Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0272989X15610780 http://scihub22266oqcxt.onion/10.1177/0272989X15610780 C5845804!5845804!26502985     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Decis+Making 2016 ; 36 (5): 567-80 Nephropedia Template TP {{tp|p=26502985|t=2016. A FRAMEWORK FOR PRIORITIZING RESEARCH INVESTMENTS IN PRECISION MEDICINE |pdf=|usr=}}{{26502985}} gab.com Text A FRAMEWORK FOR PRIORITIZING RESEARCH INVESTMENTS IN PRECISION MEDICINE JO: Med Decis Making http://www.kidney.de/pget.php?&tw=1&pmid=26502985 #FOAvip Introduction: The adoption of precision medicine (PM) has been limited in practice to date, and yet its promise has attracted research investments. Developing foundational economic approaches for directing proper use of PM and stimulating growth in this area from multiple perspectives is thus quite timely. Methods: Building on our previously developed Expected Value of Individualized Care (EVIC) framework, we conceptualize new decision-relevant metrics to better understand and forecast the expected value of PM. Several aspects of behavior at the patient, physician and the payer level are considered that can inform the rate and manner in which PM innovations diffuse throughout the relevant population. We illustrate this framework and the methods using a retrospective evaluation of the use of OncotypeDx genomic test among breast cancer patients. Results: The enriched metrics can help inform many facets of PM decision making, such as evaluating alternative reimbursement levels for PM tests, implementation and education programs for physicians and patients, and decisions around research investments by manufacturers and public entities. We replicated prior published results on evaluation of OncotypeDx among breast cancer patients, but also illustrated that those results are based on assumptions that are often not met in practice. Instead, we show how incorporating more practical aspects of behavior around PM could lead to drastically different estimates of value. Conclusion: We believe that the framework and the methods presented can provide decision makers with more decision-relevant tool to explore the value of PM. There is a growing recognition that data on adoption is important to decision makers. More research is needed to develop prediction models for potential diffusion of PM technologies. Twit Text FOAVip A FRAMEWORK FOR PRIORITIZING RESEARCH INVESTMENTS IN PRECISION MEDICINE ????Med Decis Making http://www.kidney.de/pget.php?&tw=1&pmid=26502985 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26502985 #FOAvip English Wikipedia <ref>{{Cite pmid|26502985}}</ref> A FRAMEWORK FOR PRIORITIZING RESEARCH INVESTMENTS IN PRECISION MEDICINE #MMPMID26502985 Basu A; Carlson JJ; Veenstra DL Med Decis Making 2016[Jul]; 36 (5): 567-80 PMID26502985show ga Introduction: The adoption of precision medicine (PM) has been limited in practice to date, and yet its promise has attracted research investments. Developing foundational economic approaches for directing proper use of PM and stimulating growth in this area from multiple perspectives is thus quite timely. Methods: Building on our previously developed Expected Value of Individualized Care (EVIC) framework, we conceptualize new decision-relevant metrics to better understand and forecast the expected value of PM. Several aspects of behavior at the patient, physician and the payer level are considered that can inform the rate and manner in which PM innovations diffuse throughout the relevant population. We illustrate this framework and the methods using a retrospective evaluation of the use of OncotypeDx genomic test among breast cancer patients. Results: The enriched metrics can help inform many facets of PM decision making, such as evaluating alternative reimbursement levels for PM tests, implementation and education programs for physicians and patients, and decisions around research investments by manufacturers and public entities. We replicated prior published results on evaluation of OncotypeDx among breast cancer patients, but also illustrated that those results are based on assumptions that are often not met in practice. Instead, we show how incorporating more practical aspects of behavior around PM could lead to drastically different estimates of value. Conclusion: We believe that the framework and the methods presented can provide decision makers with more decision-relevant tool to explore the value of PM. There is a growing recognition that data on adoption is important to decision makers. More research is needed to develop prediction models for potential diffusion of PM technologies. äA FRAMEWORK FOR PRIORITIZING RESEARCH INVESTMENTS IN PRECISION MEDICIN(epmc).pdf DeepDyve Pubget Overpricing